• 1.

    Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007;67:18031812.

  • 2.

    Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 2007;30:487495.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Mishra NN, Prasad T, Sharma N, et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hung 2007;54:201235.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Wiebe V, Karriker M. Therapy of systemic fungal infections: a pharmacologic perspective. Clin Tech Small Anim Pract 2005;20:250257.

  • 5.

    Deem SL. Fungal disease of birds of prey. Vet Clin North Am Exot Anim Pract 2003;6:363376.

  • 6.

    Schumacher J. Fungal diseases of reptiles. Vet Clin North Am Exot Anim Pract 2003;6:327335.

  • 7.

    Paré A, Coyle KA, Sigler L, et al. Pathogenicity of the Chrysosporium anamorph of Nannizziopsis vriesii for veiled chameleons (Chamaeleo calyptratus). Med Mycol 2006;44:2531.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Steininger C, van Lunzen J, Sobottka I, et al. Mycotic brain abscess caused by opportunistic reptile pathogen. Emerg Infect Dis 2005;11:349350.

  • 9.

    Flammer K, Nettifee Osborne JA, Webb DJ, et al. Pharmaco-kinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh). Am J Vet Res 2008;69:114121.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Voriconazole. Drug facts and comparisons 4.0. Available at: www.factsandcomparisons.com. Accessed Nov 10, 2007.

  • 11.

    Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006;9:483488.

  • 12.

    Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:30183021.

  • 13.

    Itraconazole. Drug facts and comparisons 4.0. Available at: www.factsandcomparisons.com. Accessed Nov 10, 2007.

  • 14.

    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408415.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:36233626.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000;44:28652868.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Silvanose CD, Bailey TA, Di Somma A. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole. Vet Rec 2006;159:282284.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Davis JL, Salmon JH, Papich MG. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am J Vet Res 2006;67:10701075.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997;37:535540.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Tell LA, Craigmill AL, Clemons KV, et al. Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos). J Vet Pharmacol Ther 2005;28:267274.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Martinez M. Guidance for industry. Bioequivalence guidance. US Department of Health and Human Services. FDA Center for Veterinary Medicine. Available at: www.fda.gov/cvm/guidance/bioequivalence_Oct02.pdf. Accessed Nov 8, 2006.

    • Search Google Scholar
    • Export Citation
  • 22.

    Banker GS, Rhodes C. Modern pharmaceutics. 4th ed. New York: Informa HealthCare, 2002.

  • 23.

    United States Pharmacopeial Convention. USP 28, NF 23. Stability considerations in dispensing practice. In: The United States Pharmacopeia and the National Formulary. Rockville, Md: US Pharmacopeial Convention, 2005;27272730.

    • Search Google Scholar
    • Export Citation
  • 24.

    Papich MG. Drug compounding for veterinary patients. AAPS J 2005;7:E281E287.

Advertisement

Stability and uniformity of extemporaneous preparations of voriconazole in two liquid suspension vehicles at two storage temperatures

Kyvan Q. NguyenVeterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Kyvan Q. Nguyen in
Current site
Google Scholar
PubMed
Close
 PharmD
,
Michelle G. HawkinsDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Michelle G. Hawkins in
Current site
Google Scholar
PubMed
Close
 VMD
,
Ian T. TaylorDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Ian T. Taylor in
Current site
Google Scholar
PubMed
Close
 MS
,
Valerie J. WiebeVeterinary Medical Teaching Hospital and Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Valerie J. Wiebe in
Current site
Google Scholar
PubMed
Close
 PharmD
, and
Lisa A. TellDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Lisa A. Tell in
Current site
Google Scholar
PubMed
Close
 DVM
View More View Less

Abstract

Objective—To determine the stability and distribution of voriconazole in 2 extemporaneously prepared (compounded) suspensions stored for 30 days at 2 temperatures.

Sample Population—Voriconazole suspensions (40 mg/mL) compounded from commercially available 200-mg tablets suspended in 1 of 2 vehicles. One vehicle contained a commercially available suspending agent and a sweetening syrup in a 1:1 mixture (SASS). The other vehicle contained the suspending agent with deionized water in a 3:1 mixture (SADI).

Procedures—Voriconazole suspensions (40 mg/mL in 40-mL volumes) were compounded on day 0 and stored at room temperature (approx 21°C) or refrigerated (approx 5°C). To evaluate distribution, room-temperature aliquots of voriconazole were measured immediately after preparation. Refrigerated aliquots were measured after 3 hours of refrigeration. To evaluate stability, aliquots from each suspension were measured at approximately 7-day intervals for up to 30 days. Voriconazole concentration, color, odor, opacity, and pH were measured, and aerobic and anaerobic bacterial cultures were performed at various points.

Results—Drug distribution was uniform (coefficient of variation, < 5%) in both suspensions. On day 0, 87.8% to 93.0% of voriconazole was recovered; percentage recovery increased to between 95.1% and 100.8% by day 7. On subsequent days, up to day 30, percentage recovery was stable (> 90%) for all suspensions. The pH of each suspension did not differ significantly throughout the 30-day period. Storage temperature did not affect drug concentrations at any time, nor was bacterial growth obtained.

Conclusions and Clinical Relevance—Extemporaneously prepared voriconazole in SASS and SADI resulted in suspensions that remained stable for at least 30 days. Refrigerated versus room-temperature storage of the suspensions had no effect on drug stability.

Abstract

Objective—To determine the stability and distribution of voriconazole in 2 extemporaneously prepared (compounded) suspensions stored for 30 days at 2 temperatures.

Sample Population—Voriconazole suspensions (40 mg/mL) compounded from commercially available 200-mg tablets suspended in 1 of 2 vehicles. One vehicle contained a commercially available suspending agent and a sweetening syrup in a 1:1 mixture (SASS). The other vehicle contained the suspending agent with deionized water in a 3:1 mixture (SADI).

Procedures—Voriconazole suspensions (40 mg/mL in 40-mL volumes) were compounded on day 0 and stored at room temperature (approx 21°C) or refrigerated (approx 5°C). To evaluate distribution, room-temperature aliquots of voriconazole were measured immediately after preparation. Refrigerated aliquots were measured after 3 hours of refrigeration. To evaluate stability, aliquots from each suspension were measured at approximately 7-day intervals for up to 30 days. Voriconazole concentration, color, odor, opacity, and pH were measured, and aerobic and anaerobic bacterial cultures were performed at various points.

Results—Drug distribution was uniform (coefficient of variation, < 5%) in both suspensions. On day 0, 87.8% to 93.0% of voriconazole was recovered; percentage recovery increased to between 95.1% and 100.8% by day 7. On subsequent days, up to day 30, percentage recovery was stable (> 90%) for all suspensions. The pH of each suspension did not differ significantly throughout the 30-day period. Storage temperature did not affect drug concentrations at any time, nor was bacterial growth obtained.

Conclusions and Clinical Relevance—Extemporaneously prepared voriconazole in SASS and SADI resulted in suspensions that remained stable for at least 30 days. Refrigerated versus room-temperature storage of the suspensions had no effect on drug stability.

Contributor Notes

Supported by the Center for Companion Animal Health, University of California, Davis.

Address correspondence to Dr. Hawkins.